Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2016 Jun 15;15(9):2055–2065. doi: 10.1158/1535-7163.MCT-15-1023

Figure 2. Validation of acridine derivatives as inhibitors of the IRE1α-XBP1 pathway.

Figure 2

A. Western blot analysis of a panel of UPR marker proteins in HT1080 cells untreated and treated with 300 nM Tg plus 0-30 μM of 11 acridine derivatives. β-actin was used as a loading control. Chemical structures of the compounds are displayed on top of the blots. B. The same Western blot analysis with lower concentrations (0-3 μM) for 8 out of the 11 acridine derivatives which showed profound inhibition of XBP1s in Fig. 2A.